<DOC>
	<DOCNO>NCT02417571</DOCNO>
	<brief_summary>Control blood pressure ( BP ) first thing management chronic kidney disease ( CKD ) . Although guideline suggest optimal blood pressure level , hard ass BP correctly office visit . Often discrepancy office BP out-of-office BP , include home BP ambulatory BP . Recent study report many 34 % Korean CKD patient mask hypertension , mean high BP ambulatory BP monitoring normal BP conventional office BP measurement . This study aim evaluate effect ambulatory BP-guided BP management clinical outcome CKD , compare conventional management use office BP .</brief_summary>
	<brief_title>Effect Ambulatory BP Monitoring CliniCal coUrse RenAl ouTcomE CKD</brief_title>
	<detailed_description>We hypothesize management blood pressure use ambulatory BP monitoring would obtain optimal BP control thereby would influence positively renal progression CV outcomes . In detail , eligibility criterion meet , subject undergo ambulatory BP office BP measurement baseline . After randomization , ARB ( fimasartan ) administer drug-naive subject replace RAS blocker subject current us . Dosing fimasartan adjust additional drug class add sequentially 3 month ( titration phase ) . At 3 month , ABPM perform ABPM group evaluate adequacy blood pressure control dose adjust accord ABPM result ( target BP : daytime BP &lt; 135/85 mm Hg ) . This adjustment assess 6 month ABPM . For subject office BP group , conventional care provide accord current guideline ( target BP &lt; 140/90 mm Hg ) . At 18 month , ABPM perform subject outcome measure assess .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<criteria>Office BP &gt; 130/80 mm Hg , irrespective antihypertensive medication CKD stag 34 ( estimate GFR 1559 ml/min per 1.73 m2 ) Random urine albumintocreatinine ratio &gt; 300 mg/g proteintocreatinine ration &gt; 300 mg/g dipstick albumin &gt; 1+ , case estimate GFR 4559 ml/min per 1.73 m2 Systolic BP &gt; 180 mm Hg diastolic BP &gt; 110 mm Hg Malignant hypertension Resistant hypertension ( use three kind antihypertensive drug diuretic ) Uncontrolled DM ( Hb A1c &gt; 10.0 % within 3 month eligibility assessment ) Use immunosuppressive agent within 1 month anticipate Atrial fibrillation flutter Contraindication reninangiotensin system blocker ( hypersensitivity , bilateral renal artery stenosis , single kidney , etc . ) Pregnancy Kidney recipient Participating clinical trial , except observational study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Blood pressure</keyword>
	<keyword>ambulatory blood pressure</keyword>
	<keyword>glomerular filtration rate</keyword>
</DOC>